Biological prognostic markers in diffuse large B-cell lymphoma

Cancer Control

Volumn 19, Issue 3, 2012, Pages 214-226

  Perry, Anamarija M ^a   Mitrovic, Zdravko ^b   Chan, Wing C ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b University of Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DOXORUBICIN; KI 67 ANTIGEN; LEUKOSIALIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; PROTEIN BCL 2; RITUXIMAB;

ALGORITHM; ANALYTIC METHOD; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BCL2 GENE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DISEASE MARKER; DOWN REGULATION; DRUG EFFICACY; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NEUROLOGIC DISEASE; NEXT GENERATION SEQUENCE; ONCOGENE; ONCOGENE MYC; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TESTICULAR ENLARGEMENT; TP21 GENE; TP53 GENE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84864504924     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900306     Document Type: Article

References (108)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
2. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications. A study from the Lunenburg Lymphoma Biomarker Consortium. Clin Oncol. 2007;25(7):805-812.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
4. Nicolaides C, Fountzilas G, Zoumbos N, et al. Diffuse large cell lymphomas: identifi cation of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology. 1998;55(5):405-415.
5. Wilder RB, Rodriguez MA, Medeiros LJ, et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer. 2002;94(12):3083-3088.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
7. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
8. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126.
9. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127.
10. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008;26(28):4587-4594.
11. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-1861.
12. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identifi ed by gene expression profi ling. Nature. 2000;403(6769):503-511.
13. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profi ling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
14. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996.
15. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifi es a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
16. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871-3879.
17. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):995-1007.
18. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200-207.
19. Hans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
20. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifi es diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
21. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defi ned germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109(11):4930-4935.
22. Ilić I, Mitrović Z, Aurer I, et al. Lack of prognostic signifi cance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol. 2009;90(1):74-80.
23. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immuno histochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009;100(10):1842-1847.
24. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
25. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential effi cacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
26. Malumbres R, Chen J, Tibshirani R, et al. Paraffi n-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 2008;111(12):5509-5514.
27. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes refl ecting tumor and microenvironment. Blood. 2011;118(5):1350-1358.
28. Payton JE, Grieselhuber NR, Chang LW, et al. High throughput digital quantifi cation of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest. 2009;119(6):1714-1726.
29. Williams PM, Li R, Johnson NA, et al. A novel method of amplifi cation of FFPET-derived RNA enables accurate disease classifi cation with microarrays. J Mol Diagn. 2010;12(5):680-686.
30. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732-744.
31. Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17(12):4125-4135.
32. Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007;121(5):1156-1161.
33. Jung I, Aguiar RC. MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. Br J Haematol. 2009;144(1):138-140.
34. Meyer PN, Fu K, Greiner T, et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol. 2011;135(1):54-61.
35. Cardesa-Salzmann TM, Colomo L, Gutierrez G, et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica. 2011;96(7):996-1001.
36. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
37. Scandurra M, Mian M, Greiner TC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol. 2010;151(3):221-231.
38. Chigrinova E, Mian M, Shen Y, et al. Integrated profi ling of diffuse large B-cell lymphoma with 7q gain. Br J Haematol. 2011;153(4):499-503.
39. Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139-147.
40. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large Bcell lymphoma. Blood. 2007;110(13):4396-4405.
41. Young KH, Leroy K, Møller MB, et al. Structural profi les of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112(8):3088-3098.
42. Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010;16(8):2435-2442.
43. Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int. 1999;49(12):1043-1052.
44. Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337(8):529-534.
45. Sohn SK, Jung JT, Kim DH, et al. Prognostic signifi cance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003;73(2):101-107.
46. Maartense E, Kramer MH, le Cessie S, et al. Lack of prognostic signifi cance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry. Leuk Lymphoma. 2004;45(1):101-107.
47. Visco C, Canal F, Parolini C, et al. The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica. 2006;91(5):687-690.
48. Miller TP, Lippman SM, Spier CM, et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest. 1988;82(1):370-372.
49. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profi ling Project. Blood. 2004;103(11):4251-4258.
50. Cycon KA, Rimsza LM, Murphy SP. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). Exp Hematol. 2009;37(2):184-194.
51. Rimsza LM, Chan WC, Gascoyne RD, et al. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica. 2009;94(4):596-598.
52. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377-381.
53. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
54. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):961-968.
55. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defi nes a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165(1):159-166.
56. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279-4284.
57. Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic infl uence of BCL-2 expression in diffuse large Bcell lymphoma. Leuk Lymphoma. 2007;48(6):1102-1109.
58. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, et al. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol. 2009;82(5):364-372.
59. Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011;17(24):7785-7795.
60. Schuetz JM, Johnson NA, Morin RD, et al. BCL2 expression in diffuse large B-cell lymphoma. Leukemia. 2011 Dec 22. Epub ahead of print.
61. Schrader A, Bentink S, Spang R, et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer. 2011 Sep 12. Epub ahead of print.
62. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824-7827.
63. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152-3162.
64. Rimsza LM, Leblanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffi n-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112(8):3425-3433.
65. Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205-217.
66. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large Bcell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
67. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
68. Zhang HW, Chen ZW, Li SH, et al. Clinical signifi cance and prognosis of MYC translocation in diffuse large B-cell lymphoma. Hematol Oncol. 2011;29(4):185-189.
69. Niitsu N, Okamoto M, Miura I et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777-783.
70. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327-340.
71. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331.
72. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145-156.
73. Yoon DH, Choi DR, Ahn HJ, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol. 2010;85:149-157.
74. Broyde A, Boycov O, Strenov Y, et al. Role and prognostic signifi cance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009;84(6):338-343.
75. Remold-O'Donnell E, Zimmerman C, Kenney D, et al. Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrome. Blood. 1987;70(1):104-109.
76. Knowles DM. Immunophenotypic markers useful in the diagnosis and classifi cation of hematopoietic neoplasms. In: Knowles DM, ed. Neoplastic Hematology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:93-226.
77. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111(4):488-494.
78. Gelb AB, Rouse RV, Dorfman RF, et al. Detection of immunophenotypic abnormalities in paraffi n-embedded B-lineage non-Hodgkin's lymphomas. Am J Clin Pathol. 1994;102(6):825-834.
79. Mitrovic Z, Ilic I, Nola M, et al. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma. 2009;9(2):133-137.
80. Jaffe Es, Harris NL, Vardiman JW, et al, eds. Hematopathology. Philadelphia, Pa: Elsevier Saunders; 2011.
81. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15(11):1172-1180.
82. Zamò A, Malpeli G, Scarpa A, et al. Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2005;18(11):1448-1453.
83. Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31(1):106-112.
84. Kondratiev S, Duraisamy S, Unitt CL, et al. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol. 2011;35(10):1531-1539.
85. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
86. Achten R, Verhoef G, Vanuytsel L, et al. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol. 2002;20(5):1269-1277.
87. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large Bcell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109(2):478-485.
88. Caponetti GC, Bhagavathi S, Torabi A, et al. EBV-driven diffuse large B-cell lymphoma in the elderly: a diagnostic entity? Mod Pathol. 2010;23(suppl 1). Abstract 1295.
89. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195-1202.
90. Westin J, McLaughlin P. De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma. 2010;51(1):161-163.
91. Hattab EM, Martin SE, Al-Khatib SM, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol. 2010;23(2):235-243.
92. Gualco G, Weiss LM, Barber GN, et al. Diffuse large B-cell lymphoma involving the central nervous system. Int J Surg Pathol. 2011;19(1):44-50.
93. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512-1520.
94. Booman M, Douwes J, Glas AM, et al. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol. 2006;210(2):163-171.
95. Gundrum JD, Mathiason MA, Moore DB. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab. J Clin Oncol. 2009;27(31):5227-5232.
96. Mazloom A, Fowler N, Medeiros LJ, et al. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the MD Anderson Cancer Center experience. Leuk Lymphoma. 2010;51(7):1217-1224.
97. Horne MJ, Adeniran AJ. Primary diffuse large B-cell lymphoma of the testis. Arch Pathol Lab Med. 2011;135(10):1363-1367.
98. Booman M, Douwes J, Glas AM, et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin Cancer Res. 2006;12(9):2698-2705.
99. Tirelli U, Spina M, Gaidano G, et al. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS. 2000;14(12):1675-1688.
100. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98(12):3406-3412.
101. Hoffmann C, Wolf E, Fätkenheuer G, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDSrelated lymphoma. AIDS. 2003;17(10):1521-1529.
102. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: fi nal analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107(10):3832-3840.
103. Navarro JT, Lloveras N, Ribera JM, et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica. 2005;90(5):704-706.
104. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large Bcell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-1457.
105. Hasserjian RP, Ott G, Elenitoba-Johnson KS, et al. Commentary on the WHO classifi cation of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009;2(2):77-81.
106. Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profi ling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558-566.
107. Eberle FC, Salaverria I, Steidl C, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24(12):1586-1597.
108. Grant C, Dunleavy K, Eberle FC, et al. Primary mediastinal large Bcell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011;6(3):157-163.